v3.26.3
Revenue - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Disaggregation of Revenue [Line Items]        
Total revenue $ 259,936 $ 161,709 $ 705,189 $ 423,713
Commercialization Agreement with Neuraxpharm        
Disaggregation of Revenue [Line Items]        
Accounts receivable, after allowance for credit loss 12,100   12,100  
Product revenue, net        
Disaggregation of Revenue [Line Items]        
Total revenue 240,043 159,317 677,145 417,815
Accounts receivable, after allowance for credit loss 30,700 16,700 30,700 16,700
Accrued liabilities, current 70,700 $ 34,900 70,700 $ 34,900
Product revenue, net | Commercialization Agreement with Neuraxpharm        
Disaggregation of Revenue [Line Items]        
Total revenue 7,400   22,000  
Product revenue, net | UNITED STATES        
Disaggregation of Revenue [Line Items]        
Total revenue $ 232,600   $ 655,100